Navigation Links
Selexis SA to Present and Partner at the BIO-Europe 2013 Partnering Conference
Date:10/24/2013

Geneva, Switzerland (PRWEB) October 24, 2013

Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the Company’s president and CEO, Igor Fish, Ph.D., will present, “Selexis SURE CHO-Mplus™ Libraries: Custom Solutions for Improved Recombinant Protein Production” on Tuesday, November 5 at 4:45 PM at the BIO-Europe 2013 Partnering Conference being held November 4 – 6, at the Messe Wien Exhibition and Congress Center in Vienna, Austria. The Company will be also taking part in the pre-scheduled partnering meetings.

Presentation Abstract:
Stable, high-level production of recombinant proteins requires not only elevated transcription, but also cellular systems that can accommodate all of the protein folding, metabolic, secretory transport and post-translational processing requirements of any given protein. These requirements can vary significantly from protein to protein. Leveraging data from the completed SURE CHO-M Genome and Transciptome, Selexis has engineered the SURE CHO-Mplus libraries to address expression issues such as stalled translocation, improper folding, incomplete post-translational modifications, chromosomal instability or insufficient cellular respiration. With these libraries, Selexis has been able to significantly boost expression over broad range of proteins, including large multimeric structural proteins and and difficult to express proteins.

Companies or individuals attending BIO-Europe can schedule meetings with Selexis (registration required) by visiting: http://www.ebdgroup.com/bioeurope/index.php

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

# # #

Read the full story at http://www.prweb.com/releases/selexis_bio_europe/protiens_antibodies/prweb11264432.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Selexis SA Announces Publication in Metabolic Engineering of Data Demonstrating Improvement of Therapeutic Protein Secretion with Engineered CHO Cells
2. Selexis SA to Present and Partner at the BIO-Europe Spring
3. Selexis SA to Partner and Exhibit at BIO 2013
4. Selexis SA Launches SURE CHO-Mplus™ Libraries
5. Selexis SA to Present Technology Platform Data at Cell Line Development & Engineering
6. Advancement in Biologic Protein Expression Webinar Hosted by Selexis SA
7. Selexis SA to Present Data on Improved Selection of Recombinant Protein Production Clones at the Bioprocessing Summit 2013
8. Targeted therapeutics for colon cancer to be presented at AACR meeting
9. NYU Langone experts present research, clinical advances at neurosurgeons meeting
10. Specific inhibition of autophagy may represent a new concept for treatment of kidney cancer
11. Presidential Recognition Awards presented during the 2012 AIUM Annual Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... , ... MelaKids, a Laredo-based company, has introduced a new concept for children’s ... gives us a full supply of melanin – in the back of the eye ... pigment; however, around the age of thirty, we develop a yellow-brown pigment in the ...
(Date:9/19/2017)... , ... September 19, 2017 , ... The Workgroup ... of health IT to create efficiencies in healthcare information exchange and a trusted advisor ... of their latest industry white paper, entitled Barriers to Adoption of the ERA ...
(Date:9/19/2017)... ... ... Public outrage over the toxins that exist in tap water and the lack ... itself to research, develop and ultimately supply consumers with healthy drinking water alternatives. Vitev ... alkaline water technologies, water filtration systems, and consumer education. , ...
(Date:9/19/2017)... ... September 19, 2017 , ... Bone Solutions Inc. (BSI), an ... orthopedic medical device, OsteoCrete®. OsteoCrete® bone void filler is designed to assist with ... magnesium, a critical property for bone health and development. , “We’re excited to ...
(Date:9/19/2017)... ... September 19, 2017 , ... Ron Norman, CEO of Team Decades, ... of making a distinct rather than generic impression in the job market if one ... a stack of resumes knows that the first impression they give off is not ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... Sept. 6, 2017   PDI , a leader in ... host an educational session focused on the role of ... prevention at the 2017 Annual Scientific Meeting of the ... place at the Phoenix Convention ... Sept. 16-19, will also feature PDI,s Prevantics® Device ...
(Date:9/6/2017)... 2017 Eli Lilly and Company (NYSE: ... data for galcanezumab and lasmiditan, two investigational treatments for ... Society (IHC) taking place Sept. 7-10 in ... new, long-term data from an open-label study evaluating the ... mg and 240 mg) for the prevention of migraine. ...
(Date:9/5/2017)... NEWTOWN, Pa. , Sept. 5, 2017  Xyntek Inc. has announced another ... opened a new Midwest office to meet the growing demands of customer engagements ... Xyntek's new Midwest office is located at ... ... demands of customer engagements regionally. ...
Breaking Medicine Technology: